![Checkpoint Therapeutics Inc](/common/images/company/N_CKPT.png)
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodie... Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.030735 | 0.963479623824 | 3.19 | 3.51 | 3.02 | 718320 | 3.29538524 | CS |
4 | 0.050735 | 1.60047318612 | 3.17 | 3.86 | 2.68 | 859601 | 3.15751349 | CS |
12 | -0.879265 | -21.4454878049 | 4.1 | 4.5 | 2.68 | 1374739 | 3.49310716 | CS |
26 | 0.970735 | 43.1437777778 | 2.25 | 4.5 | 2.06 | 969839 | 3.34849515 | CS |
52 | 1.220735 | 61.03675 | 2 | 4.5 | 1.38 | 680654 | 2.95950291 | CS |
156 | -17.179265 | -84.2120833333 | 20.4 | 20.8 | 1.3 | 524778 | 5.66677097 | CS |
260 | -18.779265 | -85.3602954545 | 22 | 53.762 | 1.3 | 706857 | 18.99438098 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約